To map the dynamic processes underlying the response to ICB, we utilized our bilateral tumour model to remove responsive and non-responsive tumours at 1 h prior and at 2-, 4- and 6-days following administration of anti-CTLA4/anti-PD-L1 therapy (Fig. 1a, b and Supplementary Fig. 1) and examined the transcriptomes of these tumours using RNA-sequencing. The gene discussed is CTLA4; the disease is neoplasm.